| Impact of a delirium screening tool and multifaceted education on nurses’ knowledge of delirium and ability to evaluate it correctly G Gesin, BB Russell, AP Lin, HJ Norton, SL Evans, JW Devlin American Journal of Critical Care 21 (1), e1-e11, 2012 | 167 | 2012 |
| Letermovir for primary and secondary cytomegalovirus prevention in allogeneic hematopoietic cell transplant recipients: Real‐world experience A Lin, M Maloy, Y Su, V Bhatt, L DeRespiris, M Griffin, C Lau, A Proli, ... Transplant Infectious Disease 21 (6), e13187, 2019 | 79 | 2019 |
| Influence of obesity on efficacy and toxicity of induction chemotherapy in patients with newly diagnosed acute myeloid leukemia A Lin, M Othus, A McQuary, M Chi, E Estey Leukemia & lymphoma 54 (3), 541-546, 2013 | 38 | 2013 |
| Letermovir for prevention of cytomegalovirus reactivation in haploidentical and mismatched adult donor allogeneic hematopoietic cell transplantation with post-transplantation … A Lin, J Flynn, L DeRespiris, B Figgins, M Griffin, C Lau, A Proli, ... Transplantation and cellular therapy 27 (1), 85. e1-85. e6, 2021 | 36 | 2021 |
| Extended-duration letermovir prophylaxis for cytomegalovirus infection after cord blood transplantation in adults I Politikos, C Lau, SM Devlin, S Quach, A Lin, MA Perales, GL Shah, ... Blood advances 6 (24), 6291-6300, 2022 | 14 | 2022 |
| Lack of a significant pharmacokinetic interaction between letermovir and calcineurin inhibitors in allogeneic HCT recipients KT Maples, M Maloy, S Devlin, A Lin, L DeRespiris, M Griffin, C Lau, ... Bone Marrow Transplantation 55 (8), 1687-1689, 2020 | 13 | 2020 |
| Measurement of the DNA alkylating agents busulfan and melphalan in human plasma by mass spectrometry RC Schofield, HJ Landau, SA Giralt, GL Shah, M Scordo, A Lin, E Zanutto, ... Journal of Chromatography B 1125, 121711, 2019 | 10 | 2019 |
| Analysis of cyclosporine A levels supports new dosing guidelines in adult double-unit cord blood transplant recipients to optimize immunosuppression early post-transplant V Bhatt, A Lin, K Beyer, A Proli, Y Yoo, D Ponce, J Barker Biology of Blood and Marrow Transplantation 22 (8), 1533-1534, 2016 | 10 | 2016 |
| A prospective study of dysgeusia and related symptoms in patients with multiple myeloma after autologous hematopoietic cell transplantation M Scordo, GL Shah, PA Adintori, A Knezevic, SM Devlin, ML Buchan, ... Cancer 128 (21), 3850-3859, 2022 | 8 | 2022 |
| Population pharmacokinetics of melphalan in a large cohort of autologous and allogeneic hematopoietic cell transplantation recipients: towards individualized dosing regimens GL Shah, JJ Boelens, D Carlow, A Lin, R Schofield, N Cruz Sitner, ... Clinical pharmacokinetics, 1-11, 2022 | 6 | 2022 |
| Outpatient Foscarnet Administration Incorporating Home Infusions Is Feasible Greatly Enhancing the Care of Hematopoietic Stem Cell Transplant Recipients K Beyer, M Abboud, K Hambright, A Lin, AJ Proli, V Bhatt, C Castillo, ... Biology of Blood and Marrow Transplantation 23 (3), S186, 2017 | 5 | 2017 |
| Successful personalization of propylene glycol free melphalan (PGF-MEL) for multiple myeloma (MM) and AL amyloidosis (AL) patients undergoing autologous hematopoietic stem cell … GL Shah, A Lin, A Kamrowski, CA Carino, R Schofield, SM Devlin, V Bhatt, ... Biology of Blood and Marrow Transplantation 26 (3), S154-S155, 2020 | 4 | 2020 |
| Impact of omitting post-transplant minidose-methotrexate doses in allogeneic hematopoietic cell transplantation A Lin, S Brown, M Maloy, JD Ruiz, S Devlin, L DeRespiris, A Proli, ... Leukemia & lymphoma 63 (7), 1686-1693, 2022 | 3 | 2022 |
| Feasibility and Toxicity of Pharmacokinetic (PK)-Directed Dosing of Evomela®(propylene glycol free melphalan, PGF-MEL) for Multiple Myeloma (MM) and AL Amyloidosis (AL … GL Shah, A Lin, R Schofield, C Sarubbi, EV Preston, SM Devlin, V Bhatt, ... Biology of Blood and Marrow Transplantation 24 (3), S129-S130, 2018 | 3 | 2018 |
| Pharmacokinetics and toxicities after Evomela®(propylene glycol free melphalan) with autologous hematopoietic stem cell transplant (AHCT) for multiple myeloma and AL amyloidosis GL Shah, H Landau, C Sarubbi, R Schofield, A Lin, V Bhatt, SJ Harnicar, ... Blood 130, 3296, 2017 | 3 | 2017 |
| Insurance barriers to high-cost anti-infective medications post allogeneic hematopoietic cell transplant SW Eng, G Vadakkel, WB Fingrut, S Murillo, S Brown, SM Devlin, M Cook, ... 2023 Tandem Meetings| Transplantation & Cellular Therapy Meetings of ASTCT …, 2023 | 2 | 2023 |
| Pharmacokinetics and Toxicities after Evomela®(Propylene Glycol Free Melphalan) with Hematopoietic Stem Cell Transplant (HCT) for Multiple Myeloma (MM), AL Amyloidosis (AL … GL Shah, H Landau, C Sarubbi, R Schofield, A Lin, V Bhatt, S Harnicar, ... Biology of Blood and Marrow Transplantation 24 (3), S79-S80, 2018 | 2 | 2018 |
| Feasibility, tolerability, and patient-reported outcomes with pharmacokinetic (PK)-directed dosing of Evomela®(propylene glycol free melphalan) for multiple myeloma and al … GL Shah, A Lin, R Schofield, C Sarubbi, EV Preston, SM Devlin, V Bhatt, ... Blood 130, 2023, 2017 | 2 | 2017 |
| Outcomes of rituximab for EBV viremia/post-transplant lymphoproliferative disease in CD34+ selected allogeneic hematopoietic stem cell transplantation K Poppiti, A Lin, NG Adel, P Hilden, H Castro-Malaspina Blood 128 (22), 4623, 2016 | 2 | 2016 |
| Reduced-Intensity Compared to Nonmyeloablative Conditioning in Patients with Non-Hodgkin Lymphoma Undergoing Allogeneic Hematopoietic Stem Cell Transplantation K Nath, K Peterson, S Brown, S Devlin, N Rodriguez, J Barker, S Giralt, ... Transplantation and Cellular Therapy 30 (1), 81-92, 2024 | 1 | 2024 |
